April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Electrophysiological and Morphological Changes After Intravitreal Bevacizumab Injection in Patients With Macular Edema and Choroidal Neovascularization
Author Affiliations & Notes
  • Y.-H. Ohn
    Department of Ophthalmology, Soonchunhyang Univ Hospital, Bucheon, Republic of Korea
  • H. Kim
    Department of Ophthalmology, Soonchunhyang Univ Hospital, Bucheon, Republic of Korea
  • H. Lee
    Department of Ophthalmology, Soonchunhyang Univ Hospital, Bucheon, Republic of Korea
  • J. Park
    Department of Ophthalmology, Soonchunhyang Univ Hospital, Bucheon, Republic of Korea
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5418. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y.-H. Ohn, H. Kim, H. Lee, J. Park; Electrophysiological and Morphological Changes After Intravitreal Bevacizumab Injection in Patients With Macular Edema and Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5418.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the functional and morphological changes after intravitreal bevacizumab (Avastin®) injection in patients with macular edema and choroidal neovascularization (CNV) using multifocal electroretinography (mfERG) and Optical coherence tomography (OCT).

Methods: : Intravitreal bevacizumab injections were performed on 60 eyes of 52 patients who were diagnosed as age-related macular degeneration (ARMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). mf ERG and OCT were recorded before and after the injection to analyze the macular function and central macular thickness (CMT). Mean interval from the injection to performing test was 5.6 ± 4.0 months and mean injection times were 2.4 ± 1.3.

Results: : Mean central macular thickness was reduced from 374.33± 101.4 to 249.01 ± 115.1 µm after injection. Improvement of CMT was correlated with improvement of visual acuity (p<0.05). N1 latency was decreased significantly after the injection on ring 1 (p<0.05). N2 latency and P1 latency were decreased significantly on ring 1 and 2 (p<0.05). P1 amplitude was increased significantly on ring 1 and 2 (p<0.05).

Conclusions: : Morphological and functional improvement of macula were found after intravitreal bevacizumab injection using OCT and mfERG. Results of mfERG showed that latency might be more sensitive than amplitude. These results suggest that mfERG as well as OCT may be the useful tool to assess the effect of bevacizumab in patients with macular edema and CNV.

Keywords: edema • electroretinography: clinical • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×